Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of nipocalimab in adults with moderate to severe Sjögren's disease
MOH_2025-06-05_014128Phase 3Not yet recruiting
- Sponsor
- Johnson & Johnson
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Sjögren's syndrome comparing Nipocalimab + standard of care with Placebo + standard of care (2 arms). Planned start May 2025; status: not yet recruiting.
02
Drugs
nipocalimab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on MOH_2025-06-05_014128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-06-05_014128.